NCT05794243

A Multiple-Dose Study of LY3493269 in Healthy Participants

An Open-Label, Multiple-Dose Study to Investigate the Pharmacokinetics of LY3493269 Oral Formulations Administered in a Fed or Fasted State in Healthy Participants

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to conduct blood tests to measure how much LY3493269 is in the bloodstream and how the body handles and eliminates LY3493269 when administered orally as test compared to reference formulations in healthy participants in fed and/or fasted states. The study will also evaluate the safety and tolerability of LY3493269 in these participants. The study will last up to 43 days excluding the screening period.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3493269	Administered orally.
DRUG	Sodium Caprate (C10)	Administered orally.
DRUG	Salcaprozate Sodium (SNAC)	Administered orally.

Timeline

• Start date: 2023-03-23
• Primary completion: 2023-06-20
• Completion: 2023-06-20
• First posted: 2023-04-03
• Last updated: 2025-01-14
• Results posted: 2025-01-14

Locations

1 site across 1 country: Singapore